Dataset from Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007711
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to demonstrate an improvement in Progression-Free
Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine
plus placebo in chemonaïve (not including an adjuvant regimen) patients aged ≥ 70 years with
advanced NSCLC.
创建时间：
2024-11-26
